Joshua Tate, MD
Endocrinology, Diabetes & Metabolism · Huntsville, ALNPI 1467899120
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.6% of the total across 320 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 29 manufacturers reported payments, led by Novo Nordisk at 25.1% of the total. That places this record below the midpoint for endocrinology, diabetes & metabolism clinicians in AL, where the typical reported total is $6,650.
Across 320 payments — averaging $14.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$1K
- Dexcom, Inc.$567
- Abbott$491
- Medtronic$317
- Insulet Corporation$268
- Xeris Pharmaceuticals, Inc.$217
- plus $2K from 23 others
What the payments were for
- Food & beverage$4,55199%
- Education$651%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 127 | $1,160 |
| Dexcom, Inc. | 37 | $567 |
| Abbott | 25 | $491 |
| Medtronic | 21 | $317 |
| Insulet Corporation | 19 | $268 |
| Xeris Pharmaceuticals, Inc. | 11 | $217 |
| Amgen(2 entities) | 9 | $214 |
| Lilly USA, LLC | 14 | $206 |
| Corcept Therapeutics | 10 | $185 |
| Averitas Pharma Inc. | 2 | $126 |
| AbbVie | 7 | $126 |
| Bayer | 6 | $119 |
| Sanofi-aventis U.S. LLC | 5 | $78 |
| AstraZeneca(2 entities) | 2 | $74 |
| Radius Health, Inc. | 3 | $57 |
| Boehringer Ingelheim | 3 | $55 |
| Ascendis Pharma Endocrinology Inc | 2 | $43 |
| Endo Pharmaceuticals Inc. | 2 | $42 |
| Chiesi USA, Inc. | 2 | $40 |
| Tandem Diabetes Care, Inc. | 2 | $32 |
| GRT US Holding, Inc. | 2 | $32 |
| BETA Bionics, Inc. | 2 | $31 |
| Novartis | 1 | $23 |
| Merck | 1 | $22 |
| Biohaven Pharmaceuticals, Inc. | 1 | $20 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $20 |
| Kyowa Kirin, Inc. | 1 | $18 |
| CSL Behring | 1 | $17 |
| Mannkind Corporation | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Omnipod$125
- Qutenza$110
- FREESTYLE LIBRE 3$109
- Wegovy$108
How this compares
$4,616 in reported general payments places this provider in the 40th percentile of 79 endocrinology, diabetes & metabolism providers in Alabama.
See all endocrinology, diabetes & metabolism providers in Alabama →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 343 | $379,154 |
| JardianceEmpagliflozin | 288 | $294,538 |
| OzempicSemaglutide | 227 | $237,653 |
| RybelsusSemaglutide | 118 | $141,546 |
| TrulicityDulaglutide | 106 | $121,760 |
| Tresiba Flextouch U-200Insulin Degludec | 55 | $73,443 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 77 | $69,210 |
| JanuviaSitagliptin Phosphate | 75 | $67,039 |
| FarxigaDapagliflozin Propanediol | 80 | $60,379 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 52 | $40,934 |
| Humalog Kwikpen U-100Insulin Lispro | 101 | $32,576 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 167 | $27,688 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 38 | $26,909 |
| Cinacalcet Hcl | 62 | $23,259 |
| Tresiba Flextouch U-100Insulin Degludec | 37 | $22,411 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Humalog, Insulin Lispro | $206 | $510,641493 claims |
| Novo NordiskOzempic, Rybelsus, Novolog | $1,160 | $384,437359 claims |
| Boehringer IngelheimJardiance, Tradjenta | $55 | $301,254301 claims |
| MerckJanuvia | $22 | $67,03975 claims |
| AstraZenecaFarxiga | $74 | $60,37980 claims |
| AbbVieSynthroid | $126 | $3,83348 claims |
| Sanofi-aventis U.S. LLCLantus | $78 | $1,55614 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 79 endocrinology, diabetes & metabolism providers in Alabama.
Other endocrinology, diabetes & metabolism in Huntsville
- Dwain WoodeHuntsville$78K
- Ankur JindalHuntsville$6K
- Malapuram Vasudha ReddyHuntsville$6K
- Bobby JohnsonHuntsville$4K
- Neil SchaffnerOpelika$642K
- Ralph TeagueBirmingham$487K
- Bantwal BaligaOpelika$483K
- William GarveyBirmingham$421K
- Judson MenefeeFairhope$168K
- William DebellTuscaloosa$161K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.